Why carry out this study?

Teneligliptin/canagliflozin combination tablets were recently approved in Japan for the treatment of type 2 diabetes mellitus (T2DM), but there are limited data regarding the safety and effectiveness of these combination tablets when prescribed in real-world settings.

We performed this post-marketing surveillance to obtain information regarding the real-world safety, effectiveness, and adherence among Japanese patients with T2DM who switched to these combination tablets.

What was learned from the study?

There were no new safety concerns for the teneligliptin/canagliflozin combination tablets, other than those already described in the Japanese package insert. Switching to the combination tablets was associated with improvements in HbA1c, body weight, and adherence to the prescribed antihyperglycaemic therapies.